Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

mantle cell lymphoma

- PMLiVE

Kite and Arcellx expand cell therapy partnership in deal worth over $285m

The companies' existing CART-ddBCMA collaboration now covers lymphomas

- PMLiVE

Kite and Epic Bio announce cancer cell therapy collaboration agreement

The partnership centres around Epic Bio’s proprietary gene regulation platform

- PMLiVE

Kite’s CAR-T therapies recommended by NICE for certain blood cancers

The two treatments could benefit up to 600 patients each year in England

- PMLiVE

Gilead’s Trodelvy shows promise in phase 2 bladder cancer study

An estimated 83,000 Americans will be diagnosed with bladder cancer in 2023

- PMLiVE

Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer

Around 790 people are diagnosed with acute lymphoblastic leukaemia each year in the UK

- PMLiVE

Gilead’s Trodelvy approved by FDA for metastatic breast cancer

HR+/HER2- is the most common type of breast cancer, accounting for 70% of new cases

- PMLiVE

Kite and Arcellx close multiple myeloma collaboration agreement

This haematological malignancy is the third most common  in Europe and the US and is incurable for most patients

- PMLiVE

Gilead’s CAR-T cell therapy recommended by NICE for lymphoma

Yescarta is the first CAR T-cell therapy recommended for routine use on the NHS

- PMLiVE

Gilead and EVOQ Therapeutics partner in deal potentially worth over $650m

The companies will focus on developing therapies for rheumatoid arthritis and lupus

- PMLiVE

Kite announces acquisition of Tmunity Therapeutics in latest agreement

The acquisition will include Tmunity’s ‘armoured’ CAR T technology platform

- PMLiVE

Kite and Arcellx partner to develop and commercialise multiple myeloma candidate

Arcellx is set to receive an upfront cash payment of $225m and $100m equity investment

- PMLiVE

Kite and Refuge Biotechnologies join to develop potential treatments for blood cancer

The agreement bolsters Kite’s expertise in synthetic biology for oncology

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links